Iovance Biotherapeutics, Inc.
USD4.10
+0.14 (+3.54%)
CEO
Frederick G. Vogt
IPO Date
2010-10-15
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$3.91
Prev. Close
$3.96
Day Low
$3.90
Day High
$4.17
52W Low
$1.66
52W High
$5.63
Market Cap
$1.47B
Volume
12.35M
| 2,435 |
| $3.70 |
| 13 May 2026 | Kirby Daniel Gordon | Chief Commercial Officer | M-Exempt | Disposed | 10,000 | $0.00 |
| 11 Mar 2026 | Roche Corleen M. | Chief Financial Officer | A-Award | Acquired | 132,200 | $0.00 |
| 11 Mar 2026 | Vogt Frederick G | director, officer: Interim CEO & General Counsel | A-Award | Acquired | 235,000 | $0.00 |
| 11 Mar 2026 | Puri Raj K. | Chief Regulatory Officer | A-Award | Acquired | 117,500 | $0.00 |
| 11 Mar 2026 | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer | A-Award | Acquired | 58,750 | $0.00 |
| 11 Mar 2026 | Kirby Daniel Gordon | Chief Commercial Officer | A-Award | Acquired | 132,200 | $0.00 |
| 11 Mar 2026 | BILINSKY IGOR | Chief Operating Officer | A-Award | Acquired | 117,500 | $0.00 |
| 6 Mar 2026 | Vogt Frederick G | director, officer: Interim CEO & General Counsel | M-Exempt | Acquired | 62,493 | $0.00 |